SYRE
Spyre Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
SYRE Profile
Spyre Therapeutics, Inc.
A clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases
221 Crescent Street , Building 23 , Suite 105 , Waltham, MA 02453
--
Spyre Therapeutics, Inc., was converted from a Delaware limited liability company on December 16, 2013. The company is a biotechnology company that aims to create the next generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational treatment combinations, and precision medical approaches for patient selection. Spyre's product line includes extended half-life antibodies against α4β7, TL1A and IL-23.
